Investigating the potential benefits of proton beam therapy for abdominal tumours
The use of proton beam therapy to improve outcomes in childhood abdominal tumours
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities